Ipsen S.A. (EPA:IPN)
132.80
-0.90 (-0.67%)
At close: Jan 21, 2026
Ipsen Employees
Ipsen had 5,358 employees as of December 31, 2024. The number of employees increased by 33 or 0.62% compared to the previous year.
Employees
5,358
Change (1Y)
33
Growth (1Y)
0.62%
Revenue / Employee
€701,717
Profits / Employee
€83,595
Market Cap
10.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 5,358 | 33 | 0.62% | 5,358 | 0 |
| Dec 31, 2023 | 5,325 | 253 | 4.99% | 5,325 | 0 |
| Dec 31, 2022 | 5,072 | -672 | -11.70% | 5,072 | 0 |
| Dec 31, 2021 | 5,744 | 41 | 0.72% | 5,744 | 0 |
| Dec 31, 2020 | 5,703 | -104 | -1.79% | 5,703 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| emeis Société anonyme | 83,494 |
| Sanofi | 82,878 |
| Eurofins Scientific SE | 62,696 |
| Clariane SE | 61,798 |
| Ramsay Générale de Santé | 40,494 |
| bioMérieux | 14,754 |
| Sartorius Stedim Biotech | 9,901 |
Ipsen News
- 6 days ago - Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 7 days ago - FDA Boosts Ipsen (IPSEY) with Breakthrough Therapy Designation for AML Treatment - GuruFocus
- 7 days ago - Ipsen rises on FDA breakthrough therapy status for blood cancer therapy - Seeking Alpha
- 7 days ago - FDA Grants Breakthrough Therapy Designation To Ipsen's IPN60340 In Acute Myeloid Leukemia - Nasdaq
- 8 days ago - U.S. FDA grants Ipsen's IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia - Benzinga
- 4 weeks ago - Ipsen expands early development pipeline with Simcere Zaiming's innovative antibody drug conjugate - Benzinga
- 4 weeks ago - Simcere Pharma Licenses SIM0613 To Ipsen - Nasdaq
- 3 months ago - Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript - Seeking Alpha